Optimized additive selection could help yeast-based cell-free protein expression systems fulfill their potential at commercial scale.
Indian Defence Review on MSN
A Newly Discovered Virus Weak Spot Could Change Future Treatments
Researchers discovered that polio and common cold viruses appear to rely on the same vulnerable mechanism to survive and ...
CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient ...
Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), and Dark Horse Consulting Group ('DHCG' or 'the Group ...
In 2026, biotech is delivering tangible clinical milestones, from the first AI-designed drug showing Phase IIa efficacy to the recovery of the first base-edited baby. Advances in in vivo CAR-T, ...
The biotech landscape of 2026 is defined by a convergence of forces that are no longer theoretical but are actively reshaping how drugs are discovered, tested, and approved. From the FDA's formal ...
Madrigal licensed ARO-PNPLA3 from Arrowhead for $25 million upfront and up to $975 million in milestones, expanding a liver-directed siRNA portfolio intended to pair with resmetirom. PNPLA3 silencing ...
A team of researchers has uncovered a key cellular mechanism that affects the function of mRNA vaccines and therapeutics. Their study provides the first comprehensive understanding of how mRNA ...
Researchers at the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), led by Prof. Gracjan Michlewski, ...
CRISPR-edited tumor-infiltrating lymphocytes are emerging as a promising alternative to CAR T-cell therapy for solid cancers.
MIT engineers have developed a new way to amplify the T-cell response to mRNA vaccines—an advance that could lead to much more powerful cancer vaccines and stronger protection against infectious ...
Consolidated net revenue of € 713.4 million in the first quarter of 2026, +4.9% or +8.7% on a like-for-like basis(3) at constant exchange rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results